Michael Morelli@morellifit𝕏The claim checks out against the paper. The study is the Tirzepatide and Resistance Exercise (T-REx) trial, published in Nature Medicine this week by Daniel J. Green and colleagues (the paper). It randomized 120 adults with overweight or obesity to tirzepatide plus three supervised weight-training sessions a week, or tirzepatide with usual activities, for 40 weeks.
The numbers match the post. Strength rose about 10% in the training group and fell about 10% in the group on the drug alone. Weight loss was nearly identical (about 22.3 kg with training, 22.6 kg without), and the training group lost 25% less lean tissue. The paper's own figures show the change in kilograms: bench press fell 4.09 kg on tirzepatide alone and rose 4.68 kg with training, and the other lifts moved in the same direction.
Two limits matter. The trial was open-label, so participants knew which group they were in, and the authors say so. It also measured strength in three lifts and body composition, not everyday function, falls or health outcomes. The authors call it the first randomized trial of resistance exercise combined with tirzepatide, and the Nature Medicine paper supports that description, though the post's wording is its author's own. The manufacturer supplied free drug but had no role in design or analysis, according to the University of Western Australia's release.
🕒 As of November 2026
